๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Current status of the treatment of gynecologic cancer by site. Ovary

โœ Scribed by Dr. Hugh R. K. Barber; Tae Hae Kwon


Publisher
John Wiley and Sons
Year
1976
Tongue
English
Weight
886 KB
Volume
38
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

โœฆ Synopsis


Cancer of the ovary is the leading cause of death from gynecologic cancer. The constant challenge presented by ovarian cancer is that about 11,000 women die from ovarian cancer each year and the results in 1974 are no better than have been achieved in the previous two decades. Standard practice of treatment for truly invasive common epithelial ovarian cancer includes total hysterectomy, bilateral salpingo-oophorectomy, appendectomy, omentectomy, and postsurgical insertion of tubes and administration of P3' (if the disease is of limited extent). Although it is occasionally necessary to resect isolated segments of bowel, exenterative o r ultraradical surgery i n the management of ovarian cancer is not usually chosen because of the natural history of the disease. However, aggressive surgery is indicated not so much because it is curative, but because it potentiates other forms of treatment. All stages I through IV are treated surgically, to remove as much tumor as possible without running a risk of a gastrointestinal or genitourinary fistula. Radiation therapy has been utilized in addition to the surgical therapy in stage IV to control supraclavicular and/or inguinal node involvement. Single agent alkylating chemotherapy is chosen for the treatment of common epithelial ovarian cancers. Combination chemotherapy does not produce better results at this time, except in the treatment of embryonal tumors. The treatment of the common epithelial tumors by stage is outlined. The treatment of germ cell tumors, gonadal stromal tumors, ovarian tumors in childhood, ovarian tumors in pregnancy, as well as tumors not specific for the ovary, will also be discussed.

Cancer 38: 6 10-6 19, ANCER OF THE OVARY IS THE LEADING CAUSE C of death from gynecologic cancer. The constant challenge presented by ovarian cancer is that about 11,000 w ~m e n ' ~, ~~ die each year in the United States from ovarian cancer and the results in 1974 were no better than those of the previous two decades. Since early diagnosis is a matter of chance rather than a scientific


๐Ÿ“œ SIMILAR VOLUMES


Evaluation of cervical cancer by compute
โœ Harpreet K. Pannu; Elliot K. Fishman ๐Ÿ“‚ Article ๐Ÿ“… 2003 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 76 KB

In the evaluation of cervical cancer, computed tomography (CT) is used primarily to stage advanced tumors and evaluate for recurrence. Because of reports that CT imaging lacks sensitivity and specificity in the detection of primary tumors and metastatic lesions, its use in these applications has bee

Current status of phthalocyanines in the
โœ Cynthia M. Allen; Wesley M. Sharman; Johan E. Van Lier ๐Ÿ“‚ Article ๐Ÿ“… 2001 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 101 KB

Photodynamic therapy is a binary treatment now accepted in clinic for various malignancies in several countries around the world. Phthalocyanine molecules are second-generation photosensitizers with enhanced photophysical and photochemical properties over those of porphyrins. They have been shown to